Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1GUSELKUMAB[1] Guselkumab (Guselkumab)[1] Guselkumab (Guselkumab) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[7] 37, 41, 51, 96, 97, 161, 269 💬
2Guselkumab (GUS)[1] Guselkumab (Guselkumab)[1] Guselkumab (Guselkumab) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[2] 96, 97 💬
3Guselkumab (GUS), JAK inhibitors (such as upadacitinib/tofacitinib)[3] Guselkumab (Guselkumab),
Tofacitinib,
Upadacitinib		[6] Tofacitinib citrate ,
Tofacitinib ,
Guselkumab (Guselkumab),
Upadacitinib ,
Upadacitinib tartrate ,
Upadacitinib hydrate 💬 		[5] IL23A,
JAK1,
JAK2,
JAK3,
TYK2 💬 		[44] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, C-type lectin receptor signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease, Cytokine-cytokine receptor interaction, Efferocytosis, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Hormone signaling, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pertussis, Primary immunodeficiency, Prolactin signaling pathway, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬[1] 97 💬
4Guselkumab (Tremfya)[1] Guselkumab (Guselkumab)[1] Guselkumab (Guselkumab) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[2] 96, 97 💬
5Guselkumab 100 mg[1] Guselkumab (Guselkumab)[1] Guselkumab (Guselkumab) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 37 💬
6Guselkumab Dose 1[1] Guselkumab (Guselkumab)[1] Guselkumab (Guselkumab) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[3] 51, 96, 97 💬
7Guselkumab Dose 2[1] Guselkumab (Guselkumab)[1] Guselkumab (Guselkumab) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[3] 51, 96, 97 💬
8Guselkumab Dose 3[1] Guselkumab (Guselkumab)[1] Guselkumab (Guselkumab) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[2] 96, 97 💬
9Guselkumab Dose 4[1] Guselkumab (Guselkumab)[1] Guselkumab (Guselkumab) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 96 💬
10Guselkumab Dose 5[1] Guselkumab (Guselkumab)[1] Guselkumab (Guselkumab) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 96 💬
11Guselkumab Intravenous[1] Guselkumab (Guselkumab)[1] Guselkumab (Guselkumab) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 97 💬
12Guselkumab Subcutaneous[1] Guselkumab (Guselkumab)[1] Guselkumab (Guselkumab) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[2] 96, 97 💬
13GuselkumabProduct Code: CNTO1959Pharmaceutical Form: Solution for injection in pre-filled syringeINN or Proposed INN: GuselkumabCurrent Sponsor code: CNTO1959Other descriptive name: GUSELKUMABConcentration unit: mg/ml milligram(s)/millilitreConcentration type: equalConcentration number: 100-Pharmaceutical form of the placebo: Solution for injection in pre-filled syringeRoute of administration of the placebo: Subcutaneous useProduct Name: GuselkumabProduct Code: CNTO1959Pharmaceutical Form: Solution for injection in pre-filled syringeINN or Proposed INN: GuselkumabCurrent Sponsor code: CNTO1959Other descriptive name: GUSELKUMABConcentration unit: mg/ml milligram(s)/millilitreConcentration type: equalConcentration number: 100-Pharmaceutical form of the placebo: Solution for injection in pre-filled syringeRoute of administration of the placebo: Subcutaneous use----[1] 96 💬
14GuselkumabProduct Code: CNTO1959Pharmaceutical Form: Solution for injection in pre-filled syringeINN or Proposed INN: GuselkumabCurrent Sponsor code: CNTO1959Other descriptive name: GUSELKUMABConcentration unit: mg/ml milligram(s)/millilitreConcentration type: equalConcentration number: 100-Pharmaceutical form of the placebo: Solution for injection in pre-filled syringeRoute of administration of the placebo: Subcutaneous useProduct Name: GuselkumabProduct Code: CNTO1959Pharmaceutical Form: Solution for injection in pre-filled syringeINN or Proposed INN: GuselkumabCurrent Sponsor code: CNTO1959Other descriptive name: GUSELKUMABConcentration unit: mg/ml milligram(s)/millilitreConcentration type: equalConcentration number: 100-Pharmaceutical form of the placebo: Solution for injection in pre-filled syringeRoute of administration of the placebo: Subcutaneous useProduct Name: GuselkumabProduct Code: CNTO1959Pharmaceutical Form: Solution for injection in pre-filled syringeINN or Proposed INN: GuselkumabCurrent Sponsor code: CNTO1959Other descriptive name: GUSELKUMABConcentration unit: mg/ml milligram(s)/millilitreConcentration type: equalConcentration number: 100-Pharmaceutical form of the placebo: Solution for injection in pre-filled syringeRoute of administration of the placebo: Subcutaneous use----[1] 97 💬